More Stories

Informist, Friday, Feb. 13, 2026

 

Please click here to read all liners published on this story

--Torrent Pharma Oct-Dec consol net profit INR 6.35 bln 
--Analysts saw Torrent Pharma Oct-Dec consol net profit at INR 5.99 bln 
--Torrent Pharma Oct-Dec consol revenue INR 33.03 bln 
--Analysts saw Torrent Pharma Oct-Dec consol revenue at INR 32.44 bln 
--Torrent Pharma to pay INR 29 per share interim dividend 
--Torrent Pharma Oct-Dec consol PAT INR 6.35 bln vs INR 5.03 bln year ago 
--Torrent Pharma Oct-Dec consol revenue INR 33.03 bln vs INR 28.09 bln yr ago 
--Torrent Pharma Apr-Dec consol PAT INR 17.74 bln vs INR 14.13 bln year ago 
--Torrent Pharma Oct-Dec consol operating EBITDA INR 10.9 bln vs INR 9.1 bln 
--Torrent Pharma Apr-Dec consol revenue INR 97.83 bln vs INR 85.57 bln yr ago 
--Torrent Pharma Apr-Dec consol operating EBITDA INR 32.0 bln vs INR 27.6 bln 
--Torrent Pharma Oct-Dec consol operating EBITDA margin 33% 
--Torrent Pharma Oct-Dec consol R&D spend INR 1.54 bln vs INR 1.51 bln yr ago 
--Torrent Pharma Oct-Dec India revenue INR 17.98 bln, up 14% on year 
--Torrent Pharma Oct-Dec Brazil revenue INR 3.71 bln, up 27% on yr 
--Torrent Pharma Q3 Brazil  revenue in constant currency $224 mln, up 10% YoY 
--Torrent Pharma Oct-Dec US business revenue INR 3.21 bln, up 19% on yr 
--Torrent Pharma Oct-Dec Germany revenue INR 3.04 bln, up 8% on yr 
--Torrent Pharma Oct-Dec US sales in constant currency $36 mln, up 12% YoY

 

By Divya Moolayattil

 

MUMBAI – Torrent Pharmaceuticals Ltd. reported healthy year-on-year rise in net profit and revenue for the December quarter as its business across key geographies clocked good growth. Both metrics surpassed the Street's estimates. The on-year revenue growth in the quarter under review is the strongest reported by the company in 12 quarters.

 

The pharmaceuticals company's net profit for the December quarter was INR 6.35 billion, up over 26% on year and over 7% on quarter. The Street had estimated the bottom line at INR 5.99 billion. The company's consolidated sales were INR 33.03 billion, up nearly 18% on year, also higher than the Street's estimate of INR 32.44 billion.

 

The company's expenses rose nearly 15% on year to INR 24.66 billion. Expenses growth also touched an eight-quarter high as other expenses, employee benefit expenses, and cost of raw materials climbed up.

 

Other expenses and employee benefit expenses rose nearly 14% and 19%, respectively, on year. Both expenses together account for 57% of the total expenses. The cost of raw materials rose 12% on year to INR 4.14 billion for the December quarter.

 

The revenue from India operations grew 14% on year to INR 17.98 billion owing to the strong performance of the company's chronic and sub-chronic therapies. The company's India business growth surpassed the industry's year-on-year growth of 10%.

 

In Brazil, the company's revenue increased 27% on year to INR 3.71 billion owing to the strong performance of top brands and recent launches. However, in constant currency terms, the revenue was up only 10% at 224 million Brazilian real. Torrent Pharma has 60 products under review by Brazil's Health Surveillance Agency, or Agncia Nacional de Vigilncia Sanitria. For the December quarter, its revenue from Brazil operations was more than the revenue from operations in the US, its largest market outside India.

 

In the US, the company's top line grew 19% on year to INR 3.21 billion. However, in constant currency terms, the top-line grew 12% on year to $36 million. The company said its recent launches in the US have helped it to achieve its targeted market share.

 

In Germany, the company's top line rose 8% on year to INR 3.04 billion, but in constant currency terms, the revenue was down 6% on year at 29 million euros. Torrent Pharma's growth in Germany was hit by a disruption at a third-party supplier's end.

 

The company announced an interim dividend of INR 29 per share. The dividend will be paid on or around Mar. 6.

 

For the December quarter, the company's consolidated operating earnings before interest, tax, depreciation, and amortisation grew 19% on year to INR 10.88 billion. Its EBITDA margin was 33%. Its spending on research and development increased 2% on year to INR 1.5 billion in the December quarter.

 

For the nine months ended December, Torrent Pharma's consolidated net profit grew nearly 26% on year to INR 17.74 billion and consolidated sales increased over 14% on year to INR 97.83 billion. Friday, the company's shares closed flat at INR 4,078 on the National Stock Exchange. The company declared its results after market hours.  End

 

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.